• Lakewood-Amedex Biotherapeutics reported positive preclinical results for Bisphosphocin compounds in animal models of urinary tract, pulmonary infections.
• Rodent UTI testing showed Nu-8 reduced bacterial growth versus a vehicle control, supporting continued development in resistant infections.
• Aerosol formulations showed activity in pulmonary infection models, reinforcing potential positioning in hospital-acquired pneumonia and cystic fibrosis settings.
• Nu-3 remains the lead clinical program, with a Phase 2a trial in mildly infected diabetic foot ulcers underway.
• Topline Phase 2a data are expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610070802PR_NEWS_USPR_____NY64929) on October 07, 2026, and is solely responsible for the information contained therein.